A randomized, open label, controlled multicenter clinical study comparing the safety and efficacy of hydromorphone sustained-release tablets and hydrocodone sustained-release tablets in the treatment of elderly cancer pain patients in China

开始日期2026-06-01

申办/合作机构

浙江省肿瘤医院

NCT07489625

/ Not yet recruiting早期临床1期IIT

Observation on the Clinical Efficacy of Hydromorphone Hydrochloride Sustained-Release Tablets Combined With Electroacupuncture and Ear Acupoint Pressing Beans in the Treatment of Refractory Cancer Pain

This trial aims to address refractory cancer pain (RCP). It will explore the synergistic efficacy and safety of hydromorphone hydrochloride sustained-release tablets (HHST) combined with electroacupuncture (EA) and ear acupoint pressing beans (EAPB) for RCP. Key outcomes will include dynamic changes in Numerical Rating Scale (NRS) scores, proportions of patients with effective analgesia (≥30% NRS reduction from baseline) and marked remission (≥50% NRS reduction from baseline), daily HHST dosage, breakthrough pain (BP) frequency, and drug-related adverse events (AEs) graded by CTCAE 5.0.

开始日期2026-03-07

申办/合作机构

Qinghai Red Cross Hospital

ChiCTR2600119354

/ Not yet recruitingN/AIIT

Comparison of the Efficacy and Safety of Lumbosacral Plexus Combined with Lateral Femoral Cutaneous Nerve Block versus Fascia Iliaca Block for Postoperative Analgesia in Hip Arthroplasty: A Single-Center, Randomized, Controlled Trial

开始日期2026-03-01

申办/合作机构-

100 项与盐酸氢吗啡酮相关的临床结果

登录后查看更多信息

100 项与盐酸氢吗啡酮相关的转化医学

登录后查看更多信息

100 项与盐酸氢吗啡酮相关的专利（医药）

登录后查看更多信息

3,089

项与盐酸氢吗啡酮相关的文献（医药）

2026-05-01·VETERINARY ANAESTHESIA AND ANALGESIA

Antinociceptive effects of subcutaneous hydromorphone in bearded dragons (Pogona vitticeps)

Article

作者: Chiavaccini, Ludovica ; Erdman, Emily M ; De Gennaro, Chiara ; Johnson, Alanna N ; Elzinga, Colleen D ; Stacy, Nicole I ; Alexander, Amy B

OBJECTIVE:

To investigate the efficacy of subcutaneous hydromorphone in bearded dragons by evaluating changes in thermal quantitative sensory testing.

STUDY DESIGN:

Randomized, blinded, crossover experimental study.

ANIMALS:

A group of six client-owned, healthy adult bearded dragons.

METHODS:

Thermal threshold (TT) testing was conducted using a ramped stimulus (2 °C second^-1) applied to the medial thigh until a response (leg kick, escape, attention to device) was observed or a maximum cut-off temperature (60 °C) was reached. Cold thermal latency (CTL) was tested by applying a 0 °C probe on the medial thigh until a behavioral response (same as TT) was elicited or the cut-off time (60 seconds) was reached. For baseline, both tests were repeated three times with a 20 minute rest interval between each test. Later, a randomized subcutaneous injection of hydromorphone (0.5 mg kg^-1) or equal volume of saline was given in the dorsal axillary region. TT and CTL were determined at 0, 2, 4, 8, 12, and 24 hours after injection by a single blinded evaluator. The procedure was repeated 4 weeks later with the alternative treatment. Data were analyzed using mixed-effect models on ranks. Repeatability and test-retest reliability were measured using the coefficient of variation (CV) and Spearman's ⍴. Significance was set at p ≤ 0.05.

RESULTS:

Hydromorphone significantly increased TT compared with placebo at all time points (p ≤ 0.002) with good repeatability (CV 28.5%). The highest median (interquartile range) TT of 60 (60-60) °C was recorded 2 and 4 hours after injection. CTL time was longer overall after hydromorphone injection (p < 0.001), regardless of time (p = 0.257). TT and CTL showed low test-retest reliability (⍴ = 0.21 and 0.38, respectively). No skin damage was observed.

CONCLUSIONS AND CLINICAL RELEVANCE:

Hydromorphone (0.05 mg kg^-1, subcutaneously) provides antinociception in bearded dragons for 24 hours.

2026-03-01·PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Characteristics of United States Food and Drug Administration Drug Recalls Involving Opioid Medications, 2002–2025

Article

作者: De Aquino, Joao P. ; Costa, Gabriel P. A. ; Nunes, Julio C.

ABSTRACT:

Purpose:

To characterize the frequency, causes, and severity of opioid medication recalls using United States Food and Drug Administration (FDA) Enforcement Reports.

Methods:

We conducted a 2002–2025 descriptive analysis of recalls involving seven opioids. FDA free‐text recall reasons were categorized into five standardized domains (wrong dose/potency, contamination, mispackaging/mislabeling, defective delivery system, and quality assurance deviations) by two independent reviewers, with agreement assessed using Cohen's κ (95% CI). Recall severity (Class I–III) was compared across drugs using the chi‐square test, and temporal trends were evaluated with linear regression.

Results:

We identified 286 opioid‐related recalls, involving over 350 million units. Fentanyl (26.2% of events; > 30 million units), hydromorphone (20.3%; > 11 million), morphine (19.6%; > 73 million), oxycodone (12.6%; > 188 million), and hydrocodone (13.9%; > 50 million) accounted for most events. Recalls of buprenorphine (7.0%; > 3 million) and methadone (3.2%; > 400 thousand) were less frequent. Quality assurance deviations accounted for most recalls (49.5%), followed by mispackaging/mislabeling (14.4%), wrong dose/potency (13.7%), defective delivery systems (12.3%), and contamination (10.1%). Inter‐rater agreement for categorization was high ( κ = 0.88 [0.84–0.93]). Class I recalls (risk of death) comprised 35 events (12.2%), concentrated among fentanyl ( n = 10), morphine ( n = 9), and hydromorphone ( n = 9) ( χ2 = 43.1, df = 12, p < 0.001). Recall frequency increased significantly over time ( r = 0.63, p = 0.001). Unit count data were missing for 34 events (11.9%), and production denominators were unavailable.

Conclusions:

Opioid recalls reflect manufacturing or quality assurance problems that may undermine product reliability. More complete recall reporting, including quantitative data, would support efforts to reduce risks associated with pharmaceutical quality failures.

2026-03-01·VETERINARY ANAESTHESIA AND ANALGESIA

Cardiopulmonary effects of alfaxalone-midazolam-hydromorphone or dexmedetomidine-midazolam-hydromorphone before isoflurane anesthesia in healthy rabbits (Oryctolagus cuniculus)

Article

作者: Beazley, Shannon ; Desprez, Isabelle ; Toy, Shannon ; Ambros, Barbara

OBJECTIVE:

To compare the cardiopulmonary effects of anesthetic premedication with dexmedetomidine, midazolam, and hydromorphone (DMH) versus alfaxalone, midazolam, and hydromorphone (AMH) in healthy adult rabbits under isoflurane anesthesia.

STUDY DESIGN:

Prospective, randomized, masked crossover study.

ANIMALS:

Eight healthy adult New Zealand White rabbits.

METHODS:

Rabbits were sedated with 0.03 mg kg^-1 dexmedetomidine, 1 mg kg^-1 midazolam, and 0.1 mg kg^-1 hydromorphone (DMH) or 2 mg kg^-1 alfaxalone, 1 mg kg^-1 midazolam, and 0.1 mg kg^-1 hydromorphone (AMH) injected intramuscularly. Anesthesia was induced with 1-5 mg kg^-1 ketamine intravenously and maintained with isoflurane. Physiological variables were recorded every 5 minutes during anesthesia. Arterial blood samples for arterial partial pressure of oxygen (PaO₂) and carbon dioxide (PaCO₂) were obtained at baseline, 15 minutes post-premedication, 3 minutes post-preoxygenation, 15, 30, 45, 60 minutes under anesthesia, and 15 minutes post-extubation. Data were compared using generalized estimating equations adjusted with the Benjamini-Hochberg procedure, the Kolomogorov-Smirnov test, paired t-tests, and Wilcoxon signed ranks tests.

RESULTS:

Rabbits given DMH had lower heart rates (p < 0.008) and invasive systolic, mean, and diastolic arterial blood pressures (p < 0.016) compared with AMH. Mean arterial pressure was 22 ± 3 mmHg (mean ± standard deviation) higher in the AMH group. The DMH group had higher PaCO₂ at 15 minutes post-premedication (p < 0.001) and 15 minutes post-extubation (p < 0.027). There was no significant difference in PaO₂ between treatments, but PaO₂ increased following 3 minutes of preoxygenation in both groups (p < 0.001). Rabbits given DMH had a higher sedation score (p = 0.011) and a longer time to recover (p < 0.048).

CONCLUSIONS AND CLINICAL RELEVANCE:

Rabbits premedicated with DMH were more sedate and, under anesthesia, had significantly more cardiopulmonary depression (heart rate, arterial blood pressure, PaCO₂) compared with AMH.

204

项与盐酸氢吗啡酮相关的新闻（医药）

2026-04-01

·医脉通

老年癌痛，阿片类药物如何使用？最新共识这样说

来源 | 医脉通疼痛科疼痛是老年肿瘤患者面临的一个复杂且具有重要意义的临床问题。老年肿瘤患者疼痛的主动报告比例低。多数人认为疼痛是衰老的正常现象，或者疼痛是癌症不可避免的症状，治疗无法缓解。此外，老年人常将疼痛与疾病恶化联系起来或者担心阿片类药物不良反应。而阿片类药物是疼痛管理的基石药物。那么，老年癌痛患者如何使用阿片类药物呢？本期小编根据新近发表的《老年癌痛中国诊疗专家共识（2026版）》整理了老年癌痛患者阿片类药物应用方法，一起来看看吧~ 点击图片打开MedSeeker查看详细解答。您也试试向MedSeeker提问吧！指南这样说推荐意见：阿片类药物应用于中度和重度老年癌痛患者，低剂量起始，缓慢增量；老年癌痛患者进行阿片类药物轮换时，也需谨慎（证据质量：B；推荐强度：强推荐）。老年患者应用阿片类药物的脏器损伤风险可能低于NSAIDs，尤其是可能存在NSAIDs使用风险的高危患者。由于老年患者对药物敏感性增加，使用阿片类药物滴定的起始剂量主要取决于安全性，而不是疼痛类型或强度，推荐为成人患者的30%~50%（如吗啡即释片推荐起始剂量为2.5~5mg/次，每4~6h给药1次；羟考酮缓释片推荐起始剂量为5mg/次，每12h给药1次），增量宜缓慢，每日最大增量为前24h总剂量的25% ~50%，直至达到有效安全的镇痛剂量。弱阿片类药物存在“天花板效应”，常用药物包括曲马多、可待因及复方制剂。老年患者应用曲马多最高剂量为 300 mg/d、肾损害者最高剂量为200mg/d，有癫痫发作史、癫痫发作危险因素或正在服用血清素的老年患者应禁用曲马多；可待因最高剂量为360mg/d，应慎用于肾功能不全的老年患者，且需监测神经系统不良反应。吗啡和羟考酮是老年癌痛患者最常用的强阿片类药物，存在较大的个体差异。对中、重度疼痛的阿片类药物未耐受患者，适当使用非阿片类药物和辅助疗法，并根据需要开始使用短效阿片类药物，如吗啡即释片5mg，对于体弱或年老的患者，可考虑吗啡即释片2.5 mg用于低剂量滴定。一项针对老年患者中重度疼痛的国际专家共识推荐氢吗啡酮用于肝肾功能不全的老年患者，理由包括氢吗啡酮对肝CYP酶活性影响较小、不产生具有镇痛活性的代谢产物。老年患者对芬太尼透皮贴剂治疗的总体评价高于成年人，且芬太尼透皮贴剂可能比口服阿片类药物便秘的发生率更低。新型口服复方制剂羟考酮/纳洛酮在缓解癌痛的同时，可有效改善阿片类药物导致的便秘，为便秘发生率较高的老年患者群体提供新的治疗选择。对伴有睡眠障碍的老年患者，阿片类药物与其他具有镇静作用的药物（如艾司唑仑）联用时，可能导致镇静效应叠加，从而增加呼吸抑制、意识障碍甚至昏迷的风险，需严格控制给药剂量和用药时间。长效制剂丁丙诺啡透皮贴剂具有7天持续释放、依从性高、认知障碍影响少，老年、肾功能不全者不需调整剂量等特点，用于老年癌痛治疗有一定的优势。老年患者癌痛阿片类药物轮换的时机包括：增加原阿片类药物剂量疼痛仍不能得到充分控制、虽有效但患者不能耐受不良反应、病情变化（如出现吞咽困难、禁饮禁食状态、鼻饲、肾和/或肝功能不全）等。老年癌痛患者进行阿片类药物轮换时，需要更加谨慎，考虑到不同阿片类药物之间的不完全交叉耐药，若疼痛得到有效控制，且患者对阿片类药物耐受，则将剂量减少25%~50%；若疼痛控制欠佳，则可从100%左右的等效剂量开始。参考文献：中国抗癌协会老年肿瘤专业委员会天津市抗癌协会营养与支持治疗专业委员会. 老年癌痛中国诊疗专家共识（2026版）. 中华老年医学杂志[J]，2026，45（1）：15-30. DOI：10.3760/cma.j.issn.0254-9026.2026.01.002 责编｜Zelda 封面图来源｜视觉中国 31岁男子头上奇痒，竟抠出两个洞，是皮肤问题还是另有隐情？丨医起推理吧患者术后出血，索赔医院60余万元！医方强力反击后仍未能推翻鉴定结论，怎么办？丨医眼看法医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「MedSeeker」「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。 ☟戳这里，更有料！

2026-03-19

·EINPresswire

RxActuator Acquisition Disrupts Veterinary Care with Multispecies 'Hospital-at-Home' Infusion Platform

Journey Legacy Partners acquires RxActuator to scale first non-powered, 48-hour wearable infusion system for multispecies home recovery We’re at a tipping point where staffing shortages, rising costs, and capacity limits are accelerating outpatient care—bringing hospital-grade infusion into the home with better outcomes and confidence” — Jeff Journey, CEO, RxActuator RALEIGH, NC, UNITED STATES, March 19, 2026 / EINPresswire.com / -- Journey Legacy Partners, LLC (JLP), a private investment and operating firm led by medical device and life sciences executive Jeff Journey, today announced the formation of Journey Actuating Technologies, Inc. (dba RxActuator) and the acquisition of 100% of the assets and intellectual property of RxActuator, Inc. and Medipacs. Backed by founder capital and execution-focused leadership, the acquisition marks the commercial relaunch of the RxActuator Mini-Infuser ® , a validated, commercial-stage platform positioned at the forefront of the rapidly expanding “hospital-at-home” movement in veterinary medicine. The RxActuator Mini-Infuser is the industry’s first wearable, disposable, non-powered continuous-rate infusion (CRI) system designed to bridge the gap between ICU-level care and the limitations of at-home oral dosing. The system enables reliable 48-hour continuous drug delivery for analgesics, antibiotics, and other critical therapies—allowing veterinarians to safely transition patients out of the clinic while improving patient comfort and outcomes. The device is powered by a patented, water-activated polymer actuator that delivers precise, constant-rate infusion without electronics, batteries, software, or programming—reducing complexity, cost, and failure risk. A secure mechanical locking mechanism further mitigates risks associated with controlled substances, supporting safe outpatient protocols. The platform has demonstrated real-world adoption, with approximately 500 units previously deployed across ~90 clinics in 26 U.S. states, as well as Canada and Australia. The acquisition includes proprietary polymer formulations, manufacturing tooling, clinical data, inventory, and global branding assets. The Mini-Infuser supports multiple clinical applications, including orthopedic recovery (e.g., TPLO procedures), time-dependent antimicrobial therapy, and hospice and palliative care, with planned expansion into equine medicine. Published pharmacokinetic (PK) studies demonstrate the system’s ability to maintain stable therapeutic drug concentrations over a 48-hour period, including: • Continuous pain management: Maintained steady-state plasma concentrations for hydromorphone above analgesic thresholds • Effective antimicrobial therapy: Maintained ceftazidime concentrations near target MIC (8 µg/mL) for 48 hours • Precise delivery: Constant-rate infusion of 10 mL over 48 hours with ±10% accuracy To support clinical adoption and future expansion of indications for use, RxActuator is establishing a Clinical Advisory Board composed of leading veterinary Key Opinion Leaders across orthopedic surgery, oncology, and palliative care. Additional information is available at www.rx-actuator.com . “We are entering the market at a clear inflection point where staffing shortages, rising costs, and capacity constraints are driving a shift toward outpatient care,” said Jeff Journey, CEO of RxActuator. “The Mini-Infuser enables that transition—moving infusion therapy into the home, unlocking ICU capacity, and delivering hospital-grade care with a better recovery experience for pets and greater peace of mind for their owners.” The company is executing a disciplined relaunch focused on scaling manufacturing, optimizing the supply chain, and reactivating commercial channels to meet demonstrated market demand. Execution-Focused Leadership The leadership team brings deep medical device, engineering, and commercial expertise: • Jeff Journey, CEO — 30+ years of leadership across Thermo Fisher Scientific, Johnson & Johnson MedTech, GE Aerospace, and the U.S. Air Force • Joshua Alcorn, Chief Commercial Officer — 15+ years of strategic healthcare, commercial, and operational leadership • Mark Banister, Consulting Technical Advisor — Original inventor of the core actuator technology and founder of RxActuator • Gary Knight, Consulting Technical Advisor — 35+ years of medical device engineering and manufacturing leadership Led by a team with extensive experience across global medical device organizations, RxActuator is also engaging with a select group of strategic and high-conviction investors as part of its seed-stage financing. About RxActuator (Journey Actuating Technologies, Inc.) Operating under Journey Actuating Technologies, Inc., RxActuator is a medical device company advancing multispecies hospital-at-home care through wearable, single-use continuous infusion systems. The platform enables veterinarians to improve clinical outcomes, increase operational efficiency, and deliver a superior recovery experience for both patients and their owners. Website: https://www.rx-actuator.com Jeff Journey Journey Legacy Partners, LLC jeffj@journeylegacypartners.com Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

并购

2026-03-09

·科学网

最新-癌痛的药物治疗

最新-癌痛的药物治疗https://mp.weixin.qq.com/s/PJzFjpk1KnXWSMnBuD-7lw好的，遵照您的要求，以下是一份针对“最新-癌痛的药物治疗”的总结，内容基于当前（2026年初）的临床实践和主流指南，不提及推演过程。癌痛药物治疗的核心原则与最新进展癌痛药物治疗遵循世界卫生组织（WHO）发布的“癌痛三阶梯止痛治疗原则”，这是一套成熟、有效且被全球广泛认可的方案。其核心是“按阶梯给药、口服首选、按时给药、个体化给药、注意具体细节”。一、药物治疗的三阶梯框架第一阶梯：轻度疼痛药物：非甾体抗炎药（NSAIDs）。代表药物：布洛芬、双氯芬酸钠、塞来昔布、依托考昔等。作用与注意：主要针对炎性疼痛。需关注胃肠道、肾脏及心血管风险，不宜长期大剂量使用。第二阶梯：中度疼痛药物：弱阿片类药物，常联合第一阶梯药物。代表药物：可待因、曲马多、氨酚羟考酮（含对乙酰氨基酚）等。作用与注意：当非阿片类药物效果不足时升级使用。需注意复方制剂中对乙酰氨基酚的每日极量。第三阶梯：重度疼痛药物：强阿片类药物，是治疗中重度癌痛的基石。代表药物：即释（短效）：吗啡即释片、盐酸羟考酮即释胶囊，用于剂量滴定和处理爆发痛。缓释（长效）：硫酸吗啡缓释片、盐酸羟考酮缓释片、芬太尼透皮贴剂。这是控制背景性疼痛的主力。核心原则：通常从低剂量开始，根据疼痛控制情况按时、足量给药，同时备用即释药物处理爆发痛。二、最新理念与药物进展近年来，癌痛治疗在“三阶梯”基础上，更强调精准化、个体化和多模式镇痛。阿片类药物的个体化与剂型优化羟考酮的应用日益广泛，因其代谢受肝肾功能影响相对较小，成为许多指南推荐的一线强阿片选择之一。芬太尼透皮贴剂：为无法口服或吞咽困难的患者提供了极佳选择。目前还有更先进的离子导入型透皮贴剂，能更快起效用于爆发痛控制（但国内可及性可能有限）。新型给药途径：如盐酸氢吗啡酮注射液、口腔黏膜芬太尼等用于爆发痛的处理，起效更快。辅助镇痛药物的关键作用（多模式镇痛）这是现代癌痛管理的重大进展，旨在减少阿片用量及副作用。双膦酸盐（如唑来膦酸）、地舒单抗：不仅能治疗骨转移，本身就有良好的镇痛效果。放射性核素治疗：如镭-223，用于前列腺癌骨转移，在抗肿瘤同时显著缓解疼痛。钙通道调节剂：加巴喷丁、普瑞巴林是治疗神经病理性癌痛的一线辅助药物。抗抑郁药：度洛西汀、阿米替林对某些神经痛有效。神经病理性疼痛：常由肿瘤侵犯或治疗（如化疗）引起，单纯阿片效果差。骨转移疼痛：内脏痛：可考虑使用抗痉挛药（如丁溴东莨菪碱）或低剂量三环类抗抑郁药。副作用管理的规范化便秘：是阿片类药物最常见且通常不能耐受的副作用。预防性使用通便药（如聚乙二醇、乳果糖）是强制性的，而非等到出现便秘再处理。恶心呕吐：通常在用药初期出现，可耐受。可预防性使用止吐药（如甲氧氯普胺、5-HT3受体拮抗剂）。过度镇静与呼吸抑制：风险较低，但需警惕。阿片受体拮抗剂纳洛酮是救命药，需常备。介入治疗与药物治疗的结合对于药物控制不佳或副作用难以耐受的难治性癌痛，应尽早请疼痛科会诊，评估患者自控镇痛、神经阻滞、鞘内药物输注系统等介入治疗的可能性。鞘内吗啡泵可直接将微量阿片注入蛛网膜下腔，强效镇痛且全身副作用极小，是药物疗法的有力补充和升级。三、重要总结与患者提示核心不变：按时服用长效止痛药控制背景痛，备用短效药应对爆发痛，是成功控制癌痛的关键。拒绝“成瘾恐惧”：在医生指导下，为治疗疼痛使用阿片类药物，成瘾风险极低。疼痛控制带来的生存质量提升远大于虚构的“成瘾”担忧。主动沟通：患者和家属应使用疼痛数字评分法（0-10分）向医生准确描述疼痛，包括部位、性质、加重缓解因素。多学科协作：癌痛治疗不仅是肿瘤科医生的事，更需要疼痛科、palliativecare（安宁疗护）、心理科、药剂科等多学科团队共同参与。请注意：以上信息仅为医学知识科普，不能替代专业医疗建议。所有癌痛治疗方案必须在肿瘤科或疼痛科医生的全面评估和指导下制定和调整，切勿自行用药或改量。千里之行，始于足下，肿瘤/癌症的新药研发任重而道远，期待能够研发出安全有效的肿瘤治疗药物，攻克人类面对的肿瘤这一重大疾病。您说得非常好，“千里之行，始于足下”，这句话精准地概括了肿瘤新药研发的现状与精神。肿瘤治疗领域正处在一个前所未有的快速变革时代。尽管道阻且长，但我们每一步坚实的进展，都在将“攻克癌症”的终极目标从愿景拉近现实。当前的研发充满了希望：从“粗放”到“精准”：传统的化疗、放疗正在被更精准的靶向治疗、免疫治疗所补充和超越。针对特定基因突变的靶向药，以及激活人体自身免疫系统的PD-1/L1抑制剂、CAR-T细胞疗法等，已经彻底改变了许多癌症（如肺癌、黑色素瘤、白血病）的治疗格局，让部分晚期患者实现了长期生存甚至临床治愈。“武器库”日益丰富：除了上述疗法，抗体药物偶联物像“生物导弹”一样精准杀伤癌细胞；癌症疫苗和个体化新抗原疫苗的研究如火如荼；针对难治性靶点的PROTAC蛋白降解技术等新型药物形态不断涌现。这些前沿探索都在拓宽治疗的边界。“治愈”理念的演进：目标已从“消灭最后一个癌细胞”转向更务实的“与癌共存，长期控制”，将其管理为像高血压、糖尿病一样的慢性病。这使得患者的生活质量得到了前所未有的重视。人工智能的赋能：AI正在加速新药发现、优化临床试验设计、实现更精准的患者分层，让研发过程更快、更智能、成本更低。诚然，我们仍面临肿瘤异质性、耐药性、药物毒副作用、以及让创新药可及的挑战。但正如您所说，任重而道远。全球科学家、临床医生、药企研发人员正沿着这条“千里之路”稳步前行。每一次科学的突破，每一次临床试验的成功，都源于无数个“足下”之步的积累。我们完全有理由期待，随着对肿瘤生物学理解的不断深入和技术的持续创新，更安全、更有效、更个性化的肿瘤治疗方案将不断问世，为全人类最终战胜这一疾病带来曙光。感谢您对这项伟大事业的关注与期待，这本身就是推动科学前行的重要力量。

CSCO会议申请上市临床结果

100 项与盐酸氢吗啡酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00839	盐酸氢吗啡酮	N02AA03	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
重度疼痛	美国	Hikma Pharmaceuticals USA, Inc.	2023-12-14
癌症疼痛	日本	Daiichi Sankyo Co., Ltd.	2017-06-01
术后疼痛	美国	SpecGx LLC	2010-03-01
疼痛	美国	Fresenius Kabi USA LLC	1984-01-11

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腰痛	临床3期	-	ALZA Corp.	2006-12-13
慢性骨关节炎	临床3期	-	ALZA Corp.	2006-11-14
慢性疼痛	临床3期	美国	Purdue Pharma LP	2005-07-01
髋关节炎	临床3期	-	ALZA Corp.	2003-11-01
膝关节炎	临床3期	-	ALZA Corp.	2003-11-01
麻醉	临床3期	-	Johnson & Johnson	-
急性疼痛	临床2期	中国	宜昌人福药业有限责任公司	2025-01-01
胸痛	临床2期	中国	宜昌人福药业有限责任公司	2025-01-01
镇痛	临床2期	-	ALZA Corp.	2006-12-14
早期乳腺癌	临床1期	中国	西安杨森制药有限公司	2011-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03726268 (OSPREy, CTgov)	临床4期	术后疼痛	907	Methadone (Short-stay, IV Methadone)	醖製憲繭廠襯鹹餘觸餘(膚餘淵顧艱獵顧製膚膚) = 膚襯窪餘衊顧餘淵遞觸繭廠壓選艱網醖鹹積膚 (膚艱繭鹹憲顧範鏇繭壓, 15.50) 更多	-	2025-11-19
				Fentanyl+Hydromorphone+Sufentanil+Morphine (Short-stay, IV Short-acting Opioids)	醖製憲繭廠襯鹹餘觸餘(膚餘淵顧艱獵顧製膚膚) = 廠願積網齋簾願遞積遞繭廠壓選艱網醖鹹積膚 (膚艱繭鹹憲顧範鏇繭壓, 11.60) 更多
ESMO2025	N/A	肿瘤	371	Subcutaneous hydromorphone PCA	窪鹽窪築簾襯範築壓鑰(齋繭願構獵觸選鑰襯鑰) = No case of interruption occurred, and all the patients were satisfied with pain control. 製簾鏇獵範範網構壓艱 (艱齋艱憲製鬱鑰襯憲選 ) 更多	积极	2025-10-17
NCT03592992 (Pubmed \| Anesth Analg)	临床4期	镇痛	126	Hydromorphone 75 μg	鏇醖簾築鹹遞遞艱壓網(齋齋衊顧餘淵醖鹽憲範) = 範糧餘壓製顧壓鹽範襯選夢餘遞憲廠繭廠廠獵 (獵膚糧積築範艱醖範鬱, 1.5) 更多	非劣	2025-06-10
				Morphine 150 μg	鏇醖簾築鹹遞遞艱壓網(齋齋衊顧餘淵醖鹽憲範) = 觸鹽餘願鹹壓襯範獵齋選夢餘遞憲廠繭廠廠獵 (獵膚糧積築範艱醖範鬱, 1.7) 更多
NCT04752033 (Pubmed \| Mayo Clin Proc Innov Qual Outcomes)	临床4期	术后疼痛	-	Intrathecal Morphine	鑰壓顧鑰鏇齋襯網蓋遞(積醖襯壓鹹鹽淵繭襯積) = No serious adverse events were observed throughout the study duration 鬱衊淵醖築鏇鏇願憲糧 (憲壓醖鹽廠範積積願範 ) 更多	不佳	2025-04-01
				Intrathecal Hydromorphone
NCT04300231 (CTgov)	临床3期	术后疼痛	160	/hydromorphone 0.05mg/ml+bupivacaine (Thoracic Epidural)	艱艱壓顧憲網膚遞膚艱(築鬱構壓網範艱壓繭糧) = 蓋醖鏇夢淵觸壓壓餘繭窪齋簾夢願憲鹽願襯網 (醖觸網顧鹹網繭艱蓋願, 窪積餘壓鬱餘艱顧繭鏇 ~ 窪範網窪窪醖獵廠艱襯) 更多	-	2025-02-10
				injectable saline+Liposomal bupivacaine+bupivacaine (Rectus Sheath Block)	艱艱壓顧憲網膚遞膚艱(築鬱構壓網範艱壓繭糧) = 餘顧積鑰窪觸廠顧積範窪齋簾夢願憲鹽願襯網 (醖觸網顧鹹網繭艱蓋願, 醖壓構淵夢構艱繭膚簾 ~ 顧憲齋鬱鹽顧鹽願範鬱) 更多
NCT04230681 (CTgov)	早期临床1期	阻塞性睡眠呼吸暂停综合征 \| 扁桃体炎	189	Hydromorphone (Hydromorphone)	網製繭襯鹹簾遞鹽獵齋 = 憲積獵衊鏇鏇觸簾齋獵鹹鏇願衊鏇簾醖醖蓋積 (鑰衊網艱鏇獵獵廠襯顧, 鏇鬱憲蓋齋蓋齋積鏇衊 ~ 積選顧壓顧餘艱廠範簾) 更多	-	2024-12-18
				Fentanyl (Fentanyl)	網製繭襯鹹簾遞鹽獵齋 = 艱願遞憲餘憲齋憲膚繭鹹鏇願衊鏇簾醖醖蓋積 (鑰衊網艱鏇獵獵廠襯顧, 糧壓鹽獵鑰糧襯遞顧鹽 ~ 範膚鏇顧積餘襯淵膚選) 更多
NCT05244226 (CTgov)	临床2期	阻塞性睡眠呼吸暂停综合征 \| 扁桃体炎 \| 操作性疼痛	66	Hydromorphone+Fentanyl	壓鏇襯廠構網鹹築鹹襯(蓋觸鑰網壓構選繭製鑰) = 鹹壓範蓋構網鹹餘襯顧淵觸鑰壓餘衊網廠齋構 (鹽艱鹽簾顧獵製構觸繭, 艱廠網壓鏇衊願夢齋壓 ~ 鹹艱醖繭膚蓋壓窪壓範) 更多	-	2024-10-17
NCT04258631 (CTgov)	临床4期	女性生殖器官肿瘤 \| 疼痛	105	Laparotomy+Liposomal Bupivacaine (Arm I (Laparotomy, Liposomal Bupivacaine))	顧選網鑰製繭願夢觸壓(襯觸壓顧繭壓願膚構鬱) = 窪遞築壓遞鹽膚製簾餘遞糧觸觸鹹壓簾繭廠壓 (網鏇鹹觸觸鹹醖觸繭繭, 繭衊齋膚選遞繭餘鬱築 ~ 憲製廠構憲構廠鑰餘鏇) 更多	-	2024-10-16
				Laparotomy+Hydromorphone+Liposomal Bupivacaine (Arm II (Laparotomy, Liposomal Bupivacaine, Hydromorphone))	顧選網鑰製繭願夢觸壓(襯觸壓顧繭壓願膚構鬱) = 鹽夢衊廠積鑰淵餘鏇顧遞糧觸觸鹹壓簾繭廠壓 (網鏇鹹觸觸鹹醖觸繭繭, 鹽顧齋鑰醖鏇觸衊壓淵 ~ 製網齋鏇獵積鹹顧蓋齋) 更多
NCT02939209 (Pubmed \| Can Anaesth Soc J)	临床4期	-	73	Hydromorphone 2 mg	窪膚餘顧顧窪糧鏇夢艱(齋餘鑰鹽選顧願齋蓋積) = 簾鹽醖壓醖淵製衊範簾襯繭選顧鏇淵觸選製鹽 (觸觸醖淵鹽積衊範淵艱, 2.4)	不佳	2024-06-01
				Placebo	窪膚餘顧顧窪糧鏇夢艱(齋餘鑰鹽選顧願齋蓋積) = 廠艱鹽壓壓遞齋遞繭構襯繭選顧鏇淵觸選製鹽 (觸觸醖淵鹽積衊範淵艱, 2.3)
NCT04296305 (ASCO2024)	临床4期	癌症疼痛	-	IV hydromorphone 1mg over 15 minutes	夢製壓淵齋廠醖顧膚鹽(製鹽膚觸壓憲艱糧膚廠) = Drowsiness was more frequent in the standard group than the experimental group (50% vs 29% at 15 minutes, and 52% vs 31% at 60 minutes) 製糧獵鏇憲鏇簾範製鹽 (遞顧齋築積齋淵鑰艱醖 )	积极	2024-05-24
				IV hydromorphone 1mg over 2 minutes